Oct
6
2021
On demand

Gain deeper insights into the mechanisms of immune cell killing of tumor cells: accelerate your time to answer with integrated software analysis

Understanding the processes of the immune system and interactions at a cellular level is essential to identifying and validating new targets and determining cellular therapy approaches. Advanced cell analysis tools are successfully used for unlocking the secret to immune cell interactions and potentially enabling future breakthroughs in immune-based therapies. Integrated software analysis is key component of advanced cell analysis platforms, allowing for interactive assay development and the evaluation of large data sets through multiparameter data visualization. From linking well data together to combining multiple assay outcomes to identify “hits”, integrated software analysis can quickly provide the data insights you need to accelerate the drug discovery process.

Flow cytometry has been used extensively to study immune cells, yielding information regarding cellular subtypes, activation status and viability using expression profiles and cell health markers. In recent years, live-cell analysis has become an established method by which temporal and spatial information can be gained from the interactions and resultant killing of tumor cells

  • How to generate more biologically-relevant data through simultaneous measurements of phenotypes and functions in the same well
  • How to use real-time data acquisition and analysis to accelerate the path to actionable results, even from complex data sets
  • Efficiencies from utilizing a single software solution to guide metrics, statistics, visualizations, and reports
  • How to use dynamic visualization of results to compare, identify, and rank wells in all plates across your experiment

Dr Colby Souders

Chief Scientific Officer, Abveris

Colby Souders holds a PhD in Cell and Molecular Biology from Texas A&M and prior to Abveris was part of MassBiologics of the University of Massachusetts Medical School and Kanyos Bio (now Anokion). At MassBiologics, he worked to advance monoclonal antibodies for the prevention, treatment or diagnosis of various infectious and endogenous diseases, as well as develop related platform technologies to advance and expand the MassBiologics pipeline. Later, he joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. After successful completion of multiple antibody discovery, affinity maturation and protein engineering campaigns using various in vivo and in vitro techniques, Colby joined Abveris in August of 2018. As Chief Scientific Officer, he helps guide the team to usher in a new generation of antibody discovery tools and work to build a premium discovery engine with industry-leading timelines.

Tim Dale, PhD

Head of BioAnalytics Applications, Sartorius

Tim joined Sartorius through the acquisition of Essen BioScience in 2017 and is currently Head of BioAnalytics Applications. Co-founder of the Essen BioScience European laboratories in 2009, Tim managed R&D operations. Tim’s experience in small molecule drug discovery has contributed to several candidate molecules progressing into clinical studies. He has co-authored over 20 publications relating to pharmacology, ion channels and cell-based assays.

Nicola Bevan

Manager of Cell Imaging Applications, Sartorius

Nicola Bevan manages a Cell Imaging Applications group within the European-based BioAnalytics research team where she is involved in the research and development of novel applications for the Incucyte® live-cell analysis system and iQue® high-throughput cytometer. Nicola is a highly experienced cellular pharmacologist, having worked for more than 25 years in the pharma and biotech industry in various roles including in industrial screening and early drug discovery programs.

Jeffrey Skolnik, M.D.

Senior Vice President, Clinical Development, Inovio

Dr. Skolnik leads the HPV and immuno-oncology teams at Inovio, a DNA medicines biotechnology company. Dr. Skolnik has overseen teams at both small biotechnology and large pharmaceutical companies, where he has held several leadership positions in Clinical Development and Medical Affairs. Jeffrey is a pediatric oncologist by training, and continues to serve on staff as an Attending Physician at the Children’s Hospital of Philadelphia.

SPEAKERS

Dr Colby Souders
Chief Scientific Officer, Abveris
Tim Dale, PhD
Head of BioAnalytics Applications, Sartorius
Nicola Bevan
Manager of Cell Imaging Applications, Sartorius
Jeffrey Skolnik, M.D.
Senior Vice President, Clinical Development, Inovio

You might also like

Advancing engineered cell and gene therapy with precision gene editing

D Maddalo
Danilo Maddalo
Danilo Maddalo
Group Leader, Translational Oncology, Genentech
11 November 2021
Watch now

The therapeutic gene editing solution – cell therapy for solid tumors

B Sasu,
P Sivakumar,
J Trager et al.
Barbra Sasu, PhD
Barbra Sasu, PhD
Chief Scientific Officer, Allogene Therapeutics
Pallavur Sivakumar, PhD
Pallavur Sivakumar, PhD
Scientific Vice President and Head of Discovery, Immuno-Oncology and Cell Therapy Thematic Research Center, Bristol Myers Squibb
James Trager, PhD
James Trager, PhD
Chief Scientific Officer, Nkarta Therapeutics
Jennifer Harbottle, PhD
Jennifer Harbottle, PhD
Senior Scientist, R&D, Cell and Gene Therapy, Horizon Discovery
30 September 2021
Watch now

Cell-based therapies for cancer treatment: leveraging advanced flow cytometry...

N Senutovitch,
R Fan,
T J.
Nina Senutovitch Ph.D.
Nina Senutovitch Ph.D.
Senior Scientist, Product Development, Cell Imaging, Sartorius
Professor Rong Fan
Professor Rong Fan
Professor of Biomedical Engineering, Yale University
Tamara J. Laskowski, Ph.D.
Tamara J. Laskowski, Ph.D.
Scientific Project Director, Adoptive Cell Therapy Platform, Dept. of Stem Cell Transplantation and Cellular Therapy MD Anderson Cancer Center
5 August 2021
Watch now

Key lessons for cell & gene therapy and mRNA therapeutic development from COVID-19...

S Zobbi,
V Indurthi,
C Kröner et al.
Scott Zobbi
Scott Zobbi
Senior Business Development Manager, Custom POROS Chromatography Resins, ThermoFisher Scientific
Venkata Indurthi, PhD
Venkata Indurthi, PhD
Vice President, Research and Development, Aldevron
Christoph Kröner
Christoph Kröner
Director DNA Process Development & Cap Technology, BioNTech SE
Joseph Barberio
Joseph Barberio
Director, Process Development at Strand Therapeutics Inc.
22 April 2021
Watch now

Evolving the role of gene editing in cell therapy

J Frampton,
T Thwaites,
T Meissner
Jonathan Frampton
Jonathan Frampton
Horizon Discovery at Horizon Discovery
Tristan Thwaites
Tristan Thwaites
Lead Technical Scientist at Cell and Gene Therapy Catapult
Torsten Meissner
Torsten Meissner
Postdoctoral Fellow, Department of Stem Cell & Regenerative Biology at Harvard Medical School
6 October 2020
Watch now